Lecture 29: Hereditary Hemorrhagic Telangiectasia and Other Vascular Bleeding Disorders

Hanny Al-Samkari, MD

Presentation Date:

May 14, 2026

About This Lecture

HHT is a Multisystem Hereditary Bleeding Disorder with Numerous Morbid and Potentially Fatal Manifestations.

Slide Deck

Continuing Education Credit

Hanny Al-Samkari, MD

Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
hal-samkari@mgh.harvard.edu

Speaker Disclosures

Disclosures
Dr. Al-Samkari is a member of the Second International HHT Guidelines Committee.
Universal Disclosures (financial):
Consultancy (Agios, Alnylam, Amgen, Alpine, argenx, Sobi, Sanofi, Novartis, Pharmacosmos)
Research Funding (Agios, Sobi, Amgen, Vaderis, Novartis)

Learning Objectives

> Understand the diagnosis and clinical manifestations of hereditary hemorrhagic telangiectasia.
> Properly treat bleeding in hereditary hemorrhagic telangiectasia with antifibrinolytic and antiangiogenic medications.
> Know how to manage iron deficiency and iron deficiency anemia in HHT.
> Recognize other vascular bleeding disorders, including acquired von Willebrand disease.